Pharmafile Logo
Pharmafocus logo
Advanced Search

Arexvy

Showing 3 posts of 3 posts found.

EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59

January 29, 2024
Medical Communications Arexvy, EMA, Infections and infestations, RSV

GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …

News

GSK shares new data for RSV vaccine Arexvy

October 25, 2023
Research and Development Arexvy, GSK, Immunology, RSV, Vaccine

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …

News
markus-spiske-dnbtfbnqlrc-unsplash_1

MHRA authorises GSK’s RSV vaccine for older adults

July 10, 2023
Medical Communications Arexvy, GSK, Infections and infestations, MHRA, RSV

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its Arexvy respiratory syncytial virus (RSV) …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025